Clinical Conditions Targeted by OnabotulinumtoxinA in Medicine

July 2024 in “ Toxins ”

Dilara Onan, Fatemeh Farham, Paolo Martelletti

onabotulinumtoxinA botulinum toxin type A acetylcholine transforming growth factor-beta 1 hair loss Botox

Studysummary This opinion article reviews various pathways through which onabotulinumtoxinA might work in medical treatments, highlighting applications beyond muscle paralysis, including pain inhibition and potential effects on hair loss and cancer cell apoptosis. Our plain-language summary of this paper — not a Tressless recommendation.

OnabotulinumtoxinA (BT-A) is widely used in medicine for its ability to temporarily paralyze muscles by blocking acetylcholine release, with applications extending beyond cosmetic wrinkle reduction. It is effective in treating various conditions, including neurological disorders like cerebral palsy and multiple sclerosis, urological issues, migraines, excessive sweating, and spasticity. BT-A also targets pain pathways, aiding in the treatment of migraines and neuropathic pain, and shows potential in cancer treatment by affecting cancer cell apoptosis. Additionally, BT-A is being explored for hair loss treatment by enhancing blood flow and reducing inflammation around hair follicles. The therapeutic uses of BT-A continue to expand, with repeated applications enhancing long-term benefits.

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Efficacy and Safety of Botulinum Toxin A in the Treatment of Female Pattern Hair Loss

April 2024 in “Skin research and technology”

This study suggests that while subcutaneous Botulinum Toxin Type A may offer short-term symptom improvement for female pattern hair loss, its effectiveness does not extend beyond three months.

research The Effect of Intradermal Botulinum Toxin on Androgenetic Alopecia and Its Possible Mechanism

15 citations , April 2020 in “Journal of The American Academy of Dermatology”

In this study, intradermal injection of botulinum toxin was associated with increased hair growth in men with androgenetic alopecia through the suppression of TGF-β1 secretion from dermal papilla cells.

research Effectiveness and Safety of Botulinum Toxin Type A in the Treatment of Androgenetic Alopecia

15 citations , January 2020 in “BioMed Research International”

In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.